Bio-Rad Laboratories (BIO.B) vs Smith & Nephew SNATS (SNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bio-Rad Laboratories (BIO.B) has outperformed Smith & Nephew SNATS (SNN) over the past year, gaining 28.2% versus a loss of 25.0%. Over five years, SNN leads with a -23.8% price change compared with -50.5% for BIO.B. Smith & Nephew SNATS is the larger company by market cap ($11.33 billion vs $9.76 billion), about 1.2 times the size.
On valuation, Smith & Nephew SNATS trades at a lower trailing P/E (18.4x vs 46.3x for Bio-Rad Laboratories). Smith & Nephew SNATS pays a dividend yielding 1.47%, while Bio-Rad Laboratories does not currently pay one. Bio-Rad Laboratories converts more of its revenue into profit, with a net margin of 29.4% versus 10.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIO.B | SNN |
|---|---|---|
| Share price | $365.08 | $27.06 |
| Market cap | $9.76B | $11.33B |
| 1-day change | 0.00% | +0.37% |
| YTD return | +17.50% | -17.83% |
| 1-year return | +28.15% | -24.97% |
| 5-year return | -50.54% | -23.82% |
| P/E ratio (TTM) | 46.27 | 18.41 |
| Forward P/E | — | 11.23 |
| EPS (TTM) | $7.89 | $1.47 |
| Dividend yield | 0.00% | 1.47% |
| Annual dividend | $0.00 | $0.397 |
| Revenue (latest FY) | $2.58B | $6.16B |
| Revenue growth (YoY) | +0.65% | +6.09% |
| Net income (latest FY) | $759.90M | $625.00M |
| Gross margin | 51.87% | 68.01% |
| Operating margin | 1.83% | 12.88% |
| Net margin | 29.42% | 10.14% |
| 52-week high | $365.08 | $37.51 |
| 52-week low | $244.54 | $26.12 |
| Distance from 52-week high | 0.00% | -27.86% |
| Analyst consensus | — | hold |
| Avg. price target upside | — | +19.44% |
| Average volume | 6 | 1.65M |
| Shares outstanding | 5.06M | 418.52M |
| Employees | 7,450 | 17,000 |
| Sector | Healthcare | Health Care |
| Industry | Medical Devices | Industrial Specialties |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIO.B has outperformed SNN by 53.1 percentage points over the past year.
- Bio-Rad Laboratories trades at a higher earnings multiple (46.3x vs 18.4x trailing P/E).
- Smith & Nephew SNATS offers a meaningfully higher dividend yield (1.47% vs 0.00%).
- Bio-Rad Laboratories is more profitable, keeping 29.4 cents of every revenue dollar as net income versus 10.1 cents for Smith & Nephew SNATS.
- Smith & Nephew SNATS grew revenue faster in its latest fiscal year (+6.09% vs +0.65%).
- The two companies sit in different sectors: Bio-Rad Laboratories in Healthcare and Smith & Nephew SNATS in Health Care.
About Bio-Rad Laboratories
BIO.B stock →Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.
Healthcare · Medical Devices · 7,450 employees
About Smith & Nephew SNATS
SNN stock →Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
Health Care · Industrial Specialties · 17,000 employees
BIO.B vs SNN FAQ
Which is bigger, Bio-Rad Laboratories or Smith & Nephew SNATS?
Smith & Nephew SNATS (SNN) is larger, with a market capitalization of $11.33B compared with $9.76B for Bio-Rad Laboratories (BIO.B).
Which stock has performed better over the past year, BIO.B or SNN?
BIO.B returned +28.15% over the past 12 months, compared with -24.97% for SNN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BIO.B or SNN?
SNN has the lower trailing P/E at 18.4, versus 46.3 for BIO.B. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Bio-Rad Laboratories or Smith & Nephew SNATS?
Smith & Nephew SNATS pays a dividend yielding 1.47%, while Bio-Rad Laboratories does not currently pay a regular dividend.
Are Bio-Rad Laboratories and Smith & Nephew SNATS in the same industry?
No. Bio-Rad Laboratories is in the Healthcare sector, while Smith & Nephew SNATS is in Health Care.